DOD Biotech Financials
| DOD Stock | 1.95 0.01 0.51% |
DOD |
Understanding current and past DOD Biotech Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of DOD Biotech's financial statements are interrelated, with each one affecting the others. For example, an increase in DOD Biotech's assets may result in an increase in income on the income statement.
| Foreign Associate | USA |
| Instrument | Thailand Stock View All |
| Exchange | Thailand Exchange |
| Business Address | 111 Moo 2, |
| Sector | Consumer Defensive |
| Industry | Packaged Foods |
| Benchmark | Dow Jones Industrial |
| Website | www.dodbiotech.com |
| Phone | 66 3 444 6333 |
You should never invest in DOD Biotech without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of DOD Stock, because this is throwing your money away. Analyzing the key information contained in DOD Biotech's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
DOD Biotech Key Financial Ratios
DOD Biotech's financial ratios allow both analysts and investors to convert raw data from DOD Biotech's financial statements into concise, actionable information that can be used to evaluate the performance of DOD Biotech over time and compare it to other companies across industries.| Return On Equity | 0.04 | |||
| Return On Asset | 0.0281 | |||
| Target Price | 14.0 | |||
| Beta | 1.3 | |||
| Z Score | 67.2 |
DOD Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining DOD Biotech's current stock value. Our valuation model uses many indicators to compare DOD Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across DOD Biotech competition to find correlations between indicators driving DOD Biotech's intrinsic value. More Info.DOD Biotech Public is one of the top stocks in return on equity category among its peers. It also is one of the top stocks in return on asset category among its peers reporting about 0.70 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for DOD Biotech Public is roughly 1.42 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the DOD Biotech's earnings, one of the primary drivers of an investment's value.DOD Biotech Public Systematic Risk
DOD Biotech's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. DOD Biotech volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty with a total number of output elements of thirty-one. The Beta measures systematic risk based on how returns on DOD Biotech Public correlated with the market. If Beta is less than 0 DOD Biotech generally moves in the opposite direction as compared to the market. If DOD Biotech Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one DOD Biotech Public is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of DOD Biotech is generally in the same direction as the market. If Beta > 1 DOD Biotech moves generally in the same direction as, but more than the movement of the benchmark.
DOD Biotech Thematic Clasifications
DOD Biotech Public is part of IT investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Information technology and IT services. Information Technology (IT) companies and IT service providers across different domains
This theme covers Information technology and IT services. Information Technology (IT) companies and IT service providers across different domains. Get More Thematic Ideas
| IT | View |
DOD Biotech December 15, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of DOD Biotech help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of DOD Biotech Public. We use our internally-developed statistical techniques to arrive at the intrinsic value of DOD Biotech Public based on widely used predictive technical indicators. In general, we focus on analyzing DOD Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build DOD Biotech's daily price indicators and compare them against related drivers.
| Downside Deviation | 2.52 | |||
| Information Ratio | (0.02) | |||
| Maximum Drawdown | 25.23 | |||
| Value At Risk | (4.38) | |||
| Potential Upside | 6.84 |
Other Information on Investing in DOD Stock
DOD Biotech financial ratios help investors to determine whether DOD Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in DOD with respect to the benefits of owning DOD Biotech security.